News | March 01, 2011

Heart Valve Demonstrates Durability up to 12 Years

March 1, 2011 – A bioprosthetic heart valve has demonstrated positive performance at 12 years, according to a study published in The Journal of Thoracic and Cardiovascular Surgery. The Mosaic heart valve, from Medtronic, was evaluated in patients who had aortic valve replacement (AVR) and mitral valve replacement (MVR).

The study found that the device was free of structural valve deterioration in 93.3 percent of AVR patients 60 years and older and in 95.3 percent of MVR patients 70 years and older. In addition, hemodynamic performance data showed stability up to 10 years, indicating durability of the bioprosthesis over time.

The patients in this study represent a subset of patients from the original pre?market approval (PMA) trial in the United States. They were followed for 12 years at six international centers in this prospective, nonrandomized trial. The population of the present study involved 1,029 patients who received the Medtronic Mosaic porcine bioprostheses between 1994 and 2000, including 797 patients (mean age of 69 years) who had AVR and 232 patients (mean age of 67) who had MVR.

?These strong findings address and support the intermediate? to long?term durability of the Medtronic Mosaic bioprosthesis in the aortic and mitral position,? said Eric Jamieson, M.D., professor of surgery from the University of British Columbia in Vancouver, British Columbia, and a principal investigator of the study since 1994. ?Until now, there has been limited published documentation of the durability of this newer generation of bioprosthesis. I expect these results will be reviewed favorably by cardiothoracic surgeons, especially for patients 60 years of age and older requiring aortic valve replacement and patients 70 years of age and older who are candidates for mitral valve replacement.?

The bioprosthetic heart valve, approved by the U.S. Food and Drug Administration (FDA) in 2000, is an artificial heart valve used to replace a patient’s diseased or damaged natural heart valve. Usually it replaces the aortic or mitral valve, depending on a patient’s disease condition. The third?generation valve is made of porcine (pig) tissue that is attached to a cloth?covered, flexible plastic stent. It was designed for tissue preservation and calcium mitigation.

For more information:

Related Content

Gecko Biomedical Receives CE Mark Approval for Setalum Sealant
News | Cardiovascular Surgery | September 19, 2017
Gecko Biomedical announced it has received CE Mark approval for its Setalum Sealant, allowing the company to market its...
ClearFlow Inc. Announces Positive U.S. Clinical Trial Results
News | Cardiovascular Surgery | September 08, 2017
September 8, 2017 — ClearFlow Inc.
Videos | Cardiovascular Surgery | July 19, 2017
This video educational session, provided in partnership with the American Society of Echocardiography (ASE), is title
Intensive Glycemic Control Program Produces Significant Per-Patient Cost Savings for CABG Surgery
News | Cardiovascular Surgery | May 25, 2017
A new study from Emory University observed a near-20 percent reduction in perioperative complications, a 1.2-day...
Risk of Heart Transplant Rejection Reduced by Desensitizing Patient Antibodies
News | Cardiovascular Surgery | May 23, 2017
The risk of heart transplant rejection can be reduced by desensitizing patient antibodies, according to research...
Scientists Show How Cells React to Injury From Open-Heart Surgery
News | Cardiovascular Surgery | May 04, 2017
Cedars-Sinai Heart Institute investigators have learned how cardiac muscle cells react to a certain type of injury that...
ERACS Session Highlights Need for Standardized Best Practices in Cardiac Surgery
News | Cardiovascular Surgery | May 02, 2017
The recently formed group Enhanced Recovery After Cardiac Surgery (ERACS) hosted an organizing session in Boston on...
ClearFlow Receives Frost & Sullivan New Product Innovation Award for PleuraFlow Technology
News | Cardiovascular Surgery | May 01, 2017
ClearFlow Inc. has received the prestigious 2017 Global Frost & Sullivan Award for New Product Innovation. The...
Edwards Intuity Elite sutureless aortic valve, first implants in Connecticut, WCHN, Western Connecticut Health Network
News | Cardiovascular Surgery | February 16, 2017
Western Connecticut Health Network (WCHN) cardiothoracic surgeons Cary Passik, M.D., and Robert Gallagher, M.D., were...
open-heart surgery, PCI, percutaneous coronary intervention, NOBLE trial, left main coronary artery disease, LMCAD, TCT 2016
News | Cardiovascular Surgery | November 03, 2016
Coronary artery bypass (CABG) surgery is the standard treatment for revascularization in patients with left main...
Overlay Init